Technical Analysis for ORIC - Oric Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Flat | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | -0.86% | |
| Crossed Above 200 DMA | Bullish | -0.86% | |
| Outside Day | Range Expansion | -0.86% | |
| Gapped Up | Strength | -0.86% | |
| 200 DMA Resistance | Bearish | 1.54% | |
| Crossed Above 20 DMA | Bullish | 1.54% | |
| 20 DMA Resistance | Bearish | 2.90% | |
| 200 DMA Resistance | Bearish | 2.90% | |
| Down 3 Days in a Row | Weakness | 2.90% | |
| Down 4 Days in a Row | Weakness | 2.90% |
| Alert | Time |
|---|---|
| 200 DMA Support | 26 minutes ago |
| Down 3% | about 3 hours ago |
| 60 Minute Opening Range Breakdown | about 3 hours ago |
| 200 DMA Resistance | about 3 hours ago |
| Down 2 % | about 4 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/12/2024
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatment Treatment Of Cancer Oncology Chemotherapy Antineoplastic Drugs Occupational Safety And Health Precision Medicine Specialty Drugs Cancer Therapeutics Cd73
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatment Treatment Of Cancer Oncology Chemotherapy Antineoplastic Drugs Occupational Safety And Health Precision Medicine Specialty Drugs Cancer Therapeutics Cd73
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 16.63 |
| 52 Week Low | 4.91 |
| Average Volume | 537,652 |
| 200-Day Moving Average | 9.27 |
| 50-Day Moving Average | 11.33 |
| 20-Day Moving Average | 9.00 |
| 10-Day Moving Average | 9.37 |
| Average True Range | 0.69 |
| RSI (14) | 45.05 |
| ADX | 20.96 |
| +DI | 19.91 |
| -DI | 22.57 |
| Chandelier Exit (Long, 3 ATRs) | 8.08 |
| Chandelier Exit (Short, 3 ATRs) | 9.69 |
| Upper Bollinger Bands | 10.16 |
| Lower Bollinger Band | 7.85 |
| Percent B (%b) | 0.63 |
| BandWidth | 25.59 |
| MACD Line | -0.41 |
| MACD Signal Line | -0.57 |
| MACD Histogram | 0.1599 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.72 | ||||
| Resistance 3 (R3) | 10.72 | 10.25 | 10.49 | ||
| Resistance 2 (R2) | 10.25 | 9.89 | 10.25 | 10.41 | |
| Resistance 1 (R1) | 9.78 | 9.67 | 9.55 | 9.78 | 10.33 |
| Pivot Point | 9.31 | 9.31 | 9.19 | 9.31 | 9.31 |
| Support 1 (S1) | 8.84 | 8.95 | 8.61 | 8.84 | 8.29 |
| Support 2 (S2) | 8.37 | 8.73 | 8.37 | 8.21 | |
| Support 3 (S3) | 7.90 | 8.37 | 8.14 | ||
| Support 4 (S4) | 7.90 |
